Lexicon Pharmaceuticals (LXRX) Projected to Post Quarterly Earnings on Wednesday

Lexicon Pharmaceuticals (NASDAQ:LXRX) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Lexicon Pharmaceuticals to post earnings of ($0.06) per share and revenue of $3.99 million for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.00) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.04. The firm had revenue of $21.10 million during the quarter, compared to analysts’ expectations of $9.79 million. Lexicon Pharmaceuticals had a negative return on equity of 18.64% and a negative net margin of 37.46%. On average, analysts expect Lexicon Pharmaceuticals to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Lexicon Pharmaceuticals Stock Up 4.9%

NASDAQ:LXRX opened at $2.34 on Wednesday. The stock has a 50-day simple moving average of $2.17 and a 200 day simple moving average of $1.80. Lexicon Pharmaceuticals has a 52-week low of $1.00 and a 52-week high of $2.68. The company has a market cap of $1.04 billion, a PE ratio of -33.42 and a beta of 1.05. The company has a debt-to-equity ratio of 0.24, a quick ratio of 18.77 and a current ratio of 18.80.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LXRX. Citigroup boosted their target price on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a report on Monday, May 11th. Zacks Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 3rd. Finally, Weiss Ratings raised shares of Lexicon Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $4.55.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Large investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in shares of Lexicon Pharmaceuticals by 80.1% during the third quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 25,707 shares during the period. Security National Bank of Sioux City Iowa IA acquired a new position in Lexicon Pharmaceuticals during the 4th quarter worth about $31,000. Hudson Bay Capital Management LP acquired a new position in Lexicon Pharmaceuticals during the 2nd quarter worth about $26,000. EntryPoint Capital LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $39,000. Finally, Cerity Partners LLC grew its position in shares of Lexicon Pharmaceuticals by 21.1% in the 2nd quarter. Cerity Partners LLC now owns 206,279 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 35,892 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.